Jerel Davis
Managing Director at Versant Ventures
Greater Vancouver Metropolitan Area
Overview
Work Experience
Managing Director
2011 - Current
Current companies: Ventus Tx, Turnstone, Tentarix, Santa Ana Bio, FireFly Tx, Kolm Tx, Fable Tx Previous companies: Chinook Tx (KDNY), RayzeBio, (RYZB), BlueRock (Acq. Bayer), Crispr Tx (CRSP), Repare Tx (RPTX), Quanticel Pharmaceuticals (Acq. Celgene), Akero Therapeutics (AKRO), Inception 4 (Acq. Iveric), Inception 5 (Acq. Roche), Northern Biologics (Acq. AZ and BI), Nested Tx, Graphite Bio
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Board Chair
2020
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Raised $370,150,000.00 from Michael J. Fox Foundation.
Board Member
2022
Board Member
2022
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
Raised $176,024,658.00 from Andreessen Horowitz, RTW Investments, Access Biotechnology and Google Ventures.
Board Member
2020
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology.
Raised $93,000,000.00 from Gilead Sciences, Amplitude Venture Capital, Versant Ventures and Samsara BioCapital.
Board Member
2015
Turnstone Biologics is a privately-held clinical stage biotech company.
Raised $132,699,979.00 from Brace Pharma, Ridgeback Capital, PFM Health Sciences, Point72, Northleaf Capital Partners, Surveyor Capital, Sixty Degree Capital, Teralys Capital, JM Family Enterprises and Versant Ventures.
Board Member
2020
Board Member
2022 - 2023
Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations.
Raised $125,000,000.00 from Avidity Partners, Foresite Capital, Goldman Sachs Asset Management, Section 32 and Cowen Healthcare Investments.
Lead Board Director
2019 - 2023
Board Member
2020 - 2023
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Raised $418,000,000.00 from Soleus Capital, Ally Bridge Group, Viking Global Investors, Laurion Capital Management, Wellington Management, Sands Capital Ventures and Sofinnova Investments.